Formerly known as neuromyelitis optica, NMOSD was considered a subtype of multiple sclerosis (MS) until 2004 when a specific serum antibody, shown to target extracellular conformational epitopes of the water channel protein aquaporin-4 (AQP4) [5,6,7], was detected. This evidence concerns the gene AQP4 and myeloid sarcoma.